Therapy monitoring of omalizumab in children and adolescents with severe allergic asthma
Recruiting
- Conditions
- J45.0Predominantly allergic asthma
- Registration Number
- DRKS00006046
- Lead Sponsor
- niversitätsklinikum Gießen und Marburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
severe allergic asthma
> 6 years of age
<18 years of age
informed consent of the patients and their parents
Exclusion Criteria
no severe allergic asthma
< 6 years of age
> 18 years of age
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Total IgE and free IgE concentrations in serum were determined after 6 and 12 months (Sandwich-Immunassay)
- Secondary Outcome Measures
Name Time Method Recordings of exacerbation rate, asthma control and lung function (FEV1) determined after 6 and 12 months start the omalizumab therapy